

**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 57785

**Manuscript Type:** REVIEW

**Deep diving in the PACIFIC: practical issues in stage III non-small-cell lung cancer to avoid shipwreck**

Deep diving in the PACIFIC study

#### Abstract

After publication of the PACIFIC trial results, immune checkpoint inhibitor-based immunotherapy was included in the treatment algorithm of locally-advanced non-small cell lung cancer (NSCLC). The PACIFIC trial demonstrated that 12 months of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free and overall survival in patients with unresectable stage III NSCLC. This is the first treatment in decades to successfully improve survival in this clinical setting, with manageable toxicity and without deterioration in quality of life. The integration of durvalumab in the management of locally-advanced NSCLC accentuates the need for multidisciplinary, coordinated decision-making among lung cancer specialists, bringing new challenges and controversies as well as important changes in clinical work routines. The aim of the present article is to review – from a practical, multidisciplinary perspective – the findings and implications of the PACIFIC trial. We evaluate the immunobiological basis of durvalumab as well as practical aspects related to PD-L1 determination. In addition, we

### All Sources

Match 1 of 12

|   |   |    |
|---|---|----|
| ● | <b>Internet</b> 154 words<br>crawled on 01-May-2020<br><a href="http://wclc2018.iaslc.org">wclc2018.iaslc.org</a>   | 2% |
| ● | <b>Internet - 8 sources</b> 138 words<br>crawled on 15-Jul-2020<br><a href="http://link.springer.com">link.springer.com</a>   | 2% |
| ● | <b>Internet - 21 sources</b> 114 words<br>crawled on 06-Aug-2020<br><a href="http://worldwidescience.org">worldwidescience.org</a>  | 1% |
| ● | <b>Internet - 3 sources</b> 111 words<br><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>   | 1% |
| ● | <b>Internet</b> 93 words<br>crawled on 04-Mar-2020<br><a href="http://wclc2019.iaslc.org">wclc2019.iaslc.org</a>  | 1% |
| ● | <b>Crossref - 2 sources</b> 78 words<br><a href="#">Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel et al. "Patient-reported outcomes with durvalumab after</a> | 1% |
| ● | <b>Internet</b> 70 words<br>crawled on 24-Jun-2020<br><a href="http://repositorio.unican.es">repositorio.unican.es</a>  | 1% |

Exclude Sources





国内版

国际版

Deep diving in the PACIFIC: practical issues in stage III non-small-ce



ALL

IMAGES

VIDEOS

21,000 Results

Any time ▼

## NCCN Guidelines Insights: Non–Small Cell Lung Cancer ...

<https://www.researchgate.net/publication/337779538...>

Dec 01, 2019 · **Non-small cell lung cancer** (NSCLC), accounting for more than 85% of all **lung** cancers, is one of the leading causes of **cancer**-related mortality [1]. The 5-year overall survival rate for patients ...

## Guide to the Latest Cancer Research and Treatments ...

<https://www.cancercare.org/publications/395-your...> ▼

Dec 18, 2019 · The phase **III PACIFIC** trial found that adding the immunotherapy durvalumab to radiation and chemotherapy significantly decreased the recurrence of **lung cancer** in patients with **stage III** unresectable (inoperable) **non-small cell lung cancer**. What Patients Need to Know

## Detection of epithelial growth factor receptor (EGFR ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344758>

Introduction. Tyrosine kinase inhibitors (TKIs) are today the first-line standard modality for the treatment of **stage IV non-small cell lung cancer** (NSCLC) with epithelial growth factor receptor (EGFR) mutations ().Data suggest that the EGFR mutations are found in approximately in 10% Caucasian patients and about 50% Asian-**Pacific** patients with NSCLC (2,3).

**Cited by:** 6

**Author:** Xiao-Yang Li, Jun-Feng Xiong, Tian-Ying Jia...

**Publish Year:** 2018

## Image???Guided Radiation Therapy for Non???small Cell Lung ...

<https://www.researchgate.net/publication/5549844...>

Results Overall, 33 patients with **stage III non-small cell lung cancer** were treated with proton beam therapy between December 2011 and August 2014. The median age of the eligible patients was 67 ...



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

3,090 Results

Any time ▾

## [NCCN Guidelines Insights: Non-Small Cell Lung Cancer ...](#)

<https://www.researchgate.net/publication/337779538...>

Locally advanced **non-small cell lung cancer** (NSCLC) has historically been defined as **Stage III** by the IASCLC staging. While the workup for these patients has been standardized, the treatment ...

## [Cancer treatment and survivorship statistics, 2019 ...](#)

<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21565>

Jun 11, 2019 · Jiaqi Han, Kun Tian, Jiangping Yang, Youling Gong, Durvalumab vs placebo consolidation therapy after chemoradiotherapy **in stage III non-small-cell lung cancer**: An updated **PACIFIC** trial-based cost-effectiveness analysis, **Lung Cancer**, 10.1016/j.lungcan.2020.05.011, (2020).

**Cited by:** 537**Author:** Kimberly D. Miller, Leticia Nogueira, Ange...**Publish Year:** 2019

## [Guide to the Latest Cancer Research and Treatments ...](#)

<https://www.cancer.org/publications/395-your...> ▾

Dec 18, 2019 · The phase III **PACIFIC** trial found that adding the immunotherapy durvalumab to radiation and chemotherapy significantly decreased the recurrence of **lung cancer** in patients with **stage III** unresectable (inoperable) **non-small cell lung cancer**. What Patients Need to Know

## [End-of-life care in patients with advanced lung cancer ...](#)

<https://journals.sagepub.com/doi/full/10.1177/1753465816660925>

Sep 01, 2016 · In China, a population-based study of **non-small cell lung cancer** in Shanghai, recorded 76.4% of patients diagnosed from 2011 to 2013 were at **stage III** or IV [Fan et al. 2015]. Although there have been tremendous advances in the treatment of **lung cancer**, particularly in **non-small cell lung cancer** with the progress in tyrosine-kinase inhibitors ...

**Cited by:** 11**Author:** Richard B. L. Lim**Publish Year:** 2016